Senior Director, Oncology Access (GPO)

Stemline Therapeutics; United States; On-site; USD 150,000 - 250,000; Full time

Job summary

Stemline Therapeutics is seeking a Senior Director of Oncology Access to enhance relationships with Oncology Group Purchasing Organizations and develop access strategies for community oncology practices. This role requires extensive experience in the biotech industry, particularly in market access and oncology, to ensure patient access to Stemline's innovative therapies.

Qualifications

• 10+ years in biotech/pharmaceutical industry or related healthcare field.
• 5+ years in market access account management or sales leadership.
• Experience with oncology GPO and community oncology segment.

Responsibilities

• Develop and expand relationships with Oncology Group Purchasing Organizations.
• Lead the development of access strategies at key community oncology practices.
• Manage GPO engagement and Stemline internal stakeholder coordination.

Skills

Negotiation skills

Knowledge of reimbursement modalities

Communication skills

Job description

Overview

Senior Director, Oncology Access (GPO)

Reports to Executive Director, Oncology Access

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 140 countries around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. ELZONRIS (tagraxofusp) is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). To date, Elzonris is the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelofibrosis (MF).

In Europe, Menarini Stemline also commercializes Nexpovio, a first-in-class oral exportin 1 (XPO1) inhibitor for multiple myeloma in the UK, Switzerland, European Economic Area, CIS countries, Latin America and Turkey. Nexpovio is approved for use in combination with dexamethasone for treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy; and in combination with bortezomib and dexamethasone for treatment of adult patients with multiple myeloma who have received at least one prior therapy. Nexpovio’s marketing authorization is valid in the EU Member States as well as Iceland, Liechtenstein, Norway, and Northern Ireland, and it has been commercially available in Germany and Austria since the fourth quarter of 2022.

In January 2023, Stemline Therapeutics, received U.S. FDA approval for ORSERDU (elacestrant), the first and only treatment specifically indicated for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. ESR1 mutations cause tumors to become resistant to endocrine therapy, and up to 40% of patients with ER+, HER2- mBC have tumors which harbor this mutation. ORSERDU is the first endocrine innovation in more than 20 years, and specifically addresses a major unmet need. Elacestrant is also being investigated in several clinical trials in metastatic breast cancer disease, alone or in combination with other therapies. A Marketing Authorization Application (MAA) is currently under review by the European Medicines Agency (EMA).

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumor Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB is offering in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.

Responsibilities

Opportunity

The Sr. Director, Oncology Access will develop and expand relationships with Oncology Group Purchasing Organizations, identify areas for collaboration, and lead the development of access strategies at key community oncology practices ensuring patient access to Stemline medicines. The Sr. Director, Oncology Access will be the point person for all engagement, services, and programs through the GPO and coordinating Stemline internal stakeholders (brand teams, field sales, and data/insights) that could utilize their programs. The Sr. Director, Oncology Access will also be the Stemline lead in developing engagement plans for key GPO advisory members and large practice decision makers that impact national level access dynamics in the community oncology setting.

Responsibilities

• Serve as lead for Stemline relationship and engagement with assigned oncology GPO accounts
• Support the launch planning process for Stemline products by developing product access strategies and tactics for GPO engagement and key community oncology practices
• Develop account plans for assigned GPOs designed to ensure optimal access for Stemline products in a competitive and dynamic marketplace
• Identify competitive threats and develop response strategies to ensure optimal GPO access for product
• Lead cross functional access planning for key strategic practices which includes engagement of key personnel involved in formulary/pathway decision making and ensuring all Stemline resources are used effectively to convey the value of our medicines to the practices and their patients
• Responsible for integrating the GPO account plan and management activities across other business units and brand teams to include clear objectives, timelines, and accountability.
• Compliantly engage Medical Affairs resources to support optimal product access across assigned accounts
• Organize cross functional evaluation of GPO educational, promotional, engagement, and data offerings to maximize high value opportunities to partner with GPO and engage with their members
• Organize GPO contract pull through by leading cross functional collaboration and execution among other field colleagues
• Manage GPO meeting planning and attendance to maximize the engagement and Stemline branding opportunities
• Lead the budgeting, development, and execution of GPO engagement programs such as speaker programs, podium programs, and focus groups including managing internal approvals and cross functional planning
• Work collaboratively with all Stemline strategic partner

Qualifications

Competencies & Job Qualifications:

Technical:

• In-depth knowledge of product prescribing information
• Well-developed negotiation skills.
• A high level of awareness and understanding of the implications and opportunities of contract strategy.
• Deep knowledge of the patient and product journey for both infused and oral oncology products.
• A thorough knowledge of strategic marketing and selling.
• An in-depth knowledge of key account selling for targeted channels/segments.
• Proficiency with software applications and customer relationship management tools.
• A high level of knowledge of current reimbursement modalities, including AWP, WAC, ASP, margin, spread, and MAC pricing.
• A thorough understanding of all corporate policies and procedures.
• Thorough understanding of Patient Support and Services.
• An in-depth knowledge of the marketplace and applies that understanding to targeted account segment marketing, distribution strategy development and implementation to accomplish business objectives.
• The ability to influence key decision makers in targeted account segments.

Planning and Analysis:

• Plan, organize, and analyze in order to accomplish company and individual sales and business objectives.
• Maintain ability to develop, plan specific activities, implement, monitor, and adjust all-inclusive pull through plans that involve sales and sales management.
• Develop and update business plans for Director owned accounts and lead the development and execution of Key Account business plans.
• Manage expenses within set budgetary guidelines.
• Manage all assigned accounts through proper use of travel and administrative time.
• Maintain accurate account profiles and customer interactions via CRM.

Communication:

• Strong oral, written, and group communication skills with internal and external customers.
• Effective communication with targeted national accounts including C-suite customers.
• In a timely and accurate manner, submit all budgetary information, expense reports and administrative reports as requested.

Required:

• 10+ years of proven success in biotech/pharmaceutical industry or related healthcare field.
• Minimum of 5 years’ combined experience in market access account management (corporate accounts, GPO, payer accounts) and/or sales leadership
• Significant experience and knowledge of the oncology GPO and community oncology segment including established relationships with key GPO and/or member practice personnel
• Advanced knowledge of reimbursement and access related to provider administered (buy/bill) products including influence of pathways, payer coverage, reimbursement policies and processes, patient services, and GPO contracting
• Oncology market access launch experience of new products/start-up experience a plus
• Experience integrating Health Economics and Medical Affairs resources into access planning
• Demonstrated ability to collaborate with a diverse matrix of internal stakeholders (e.g., Market Access Account team, Corporate Accounts, field sales, brand marketing, Medical, legal, compliance, Trade, Patient Services, Data & Analytics) to achieve access goals.
• Ability to identify future policies, practices and trends that will affect community oncology practice management and access decision making in the marketplace
• Experience leading pull through efforts with sales leadership and field sales teams
• Excellent communication, presentation and negotiation skills required
• Willingness to travel up to 50 percent of time, including some weekend availability for GPO meetings

Please note--this position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.

Menarini Stemline is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.